{
    "nct_id": "NCT06215521",
    "official_title": "A Phase I, Single-Dose, Randomized, Partially Double-Blind, Placebo- and Positive-Controlled, 3-Way Crossover Study to Evaluate the Effect of LOXO-305 on QTc Interval in Healthy Subjects",
    "inclusion_criteria": "* Must have Body mass index (BMI) within the range of 18.0 to 32.0 kilograms per square meter (kg/mÂ²), inclusive at Screening\n* Male and female participants in good health, determined by no clinically significant findings from medical history, 12-lead Electrocardiogram (ECG), vital sign measurements, or clinical laboratory evaluations as assessed by the investigator\n* Female participants of non-childbearing potential and male participants who follow standard contraceptive methods\n* Must have comply with all study procedures, including the 15-night stay at the Clinical Research Unit (CRU) and follow-up phone call\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
    "exclusion_criteria": "* History or presence of any diseases or conditions of clinical significance by the Investigator (or designee) and/or Sponsor\n* Positive serologic test for hepatitis B surface antigen (HBsAg), hepatitis B virus immunoglobulin M (HBV IgM) core antibody, hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antibody at Screening.\n* Positive polymerase chain reaction (PCR) test for COVID-19 at Screening\n* Known ongoing alcohol and/or drug abuse within 2 years prior to Screening\n* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee)\n* Have previously received pirtobrutinib (LOXO-305) in any other study investigating pirtobrutinib (LOXO-305), within 30 days prior to Day 1",
    "miscellaneous_criteria": ""
}